logo
新闻中心
News Center
Check category

Heavy! National Key Monitoring Drugs List (with list)

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2019-07-11 17:28
  • Views:

(Summary description) On the afternoon of July 1, the Medical and Health Administration of the National Health and Health Commission issued the "Notice on Printing and Distributing the First Batch of National Key Monitoring and Rational Drugs (Chemicals and Biological Products)".

Heavy! National Key Monitoring Drugs List (with list)

(Summary description) On the afternoon of July 1, the Medical and Health Administration of the National Health and Health Commission issued the "Notice on Printing and Distributing the First Batch of National Key Monitoring and Rational Drugs (Chemicals and Biological Products)".

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2019-07-11 17:28
  • Views:
Information

     On the afternoon of July 1, the Medical and Health Administration of the National Health and Health Commission issued the "Notice on Printing and Distributing the First Batch of National Key Monitoring and Rational Drugs (Chemicals and Biological Products)".

1

Here is the notification content:

       The provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps Health and Health Committee and the Chinese Medicine Administration:

       In order to implement the "Opinions on Strengthening the Performance Appraisal of Three-Level Public Hospitals" of the General Office of the State Council and the Notice of the National Health and Health Commission on the Relevant Work on the Clinical Application Management of Auxiliary Drugs, the National Health and Health Committee and the State Administration of Traditional Chinese Medicine are in various places. Based on the provincial-level recommended catalogue, the first batch of national key monitoring and rational drug use lists (chemicals and biological products) (hereinafter referred to as the “Catalogue”) was formed.

It is now printed and distributed to you for use in strengthening the management of rational drug use and performance appraisal of public hospitals, and proposes the following work requirements:

I. Develop a catalogue of provincial and medical institutions

       The provincial health administrative departments shall, together with the competent authorities of Chinese medicine, form a catalogue of provincial key monitoring and rational drug use drugs on the basis of the Catalogue and publish them. After the announcement, it will be reported to the National Health and Health Commission and the State Administration of Traditional Chinese Medicine for the record. On the basis of the provincial catalogue, all types of medical institutions at all levels form a catalogue of key drugs for monitoring and rational use of drugs. The catalogues of provincial and medical institutions shall be announced to the public in the form of government affairs disclosure, public affairs disclosure, and official website publicity in accordance with the requirements.

Second, focus on monitoring the clinical application of drugs in the catalog

       All medical institutions shall establish a centralized management system for rational drug use and strengthen the management of clinical applications of drugs in the catalogue. Further standardize the prescription behavior of physicians, formulate medication guidelines or technical specifications for drugs included in the catalogue, and clearly define the conditions and principles for clinical application. If there are related medication guidelines or guidelines, they should be implemented in strict accordance with the guidelines or principles. Prescribe reviews and prescriptions for all drugs included in the catalog, and enhance the publicity, feedback and utilization of the results of prescription reviews. For the varieties with outstanding irrational use of drugs, take measures such as ranking notification, rectification within a time limit, and clearing out the drug supply catalogue of the institution to ensure rational use of drugs.

Third, strengthen the prescription management of drugs outside the catalogue

       For chemical drugs and biological products not included in the catalogue, physicians must strictly implement the "Prescription Management Measures" and other relevant regulations, and rationally select the drug varieties, drug delivery routes, and the indications according to the indications, the guidelines for the diagnosis and treatment of diseases, and the corresponding prescription authority. The dose is administered and prescribed.

       For traditional Chinese medicine, Chinese medicine practitioners should prescribe Chinese medicines in accordance with the "Guidelines for the Clinical Application of Chinese Medicines", "Regulations on the Management of Hospital Chinese Herbal Pieces", etc., in accordance with the basic principles of syndrome differentiation and treatment of traditional Chinese medicine.

       Other types of physicians, after not less than one year of systematically studying TCM professional knowledge and passing the examination, can issue prescriptions for proprietary Chinese medicines in accordance with the basic principles of syndrome differentiation and treatment of traditional Chinese medicine; obtain Chinese medicine practitioners recognized by the education administrative department at or above the provincial level. Those who have a combination of Western medicine and ethnomedicine or a degree, or participate in a two-year Western medicine learning Chinese medicine training course approved by the provincial department of Chinese medicine (the total number of hours of study is not less than 850 hours) and obtain the corresponding certificate, or The medical faculty and the stipulations of the Qualification Examination for the Qualifications of the Physicians and Physicians must be prescribed by the Chinese Medicine Masters, or they can prescribe the Chinese Medicine Decoction.

Fourth, strengthen the clinical use monitoring and performance appraisal of drugs

       Health administrative departments at all levels, competent departments of Chinese medicine and medical institutions shall establish and improve the clinical use monitoring and super-warning system for drugs.

       Focus on the clinical use of drugs included in the catalogue as the assessment content of medical institutions and their main responsible persons, combined with medical institution calibration, evaluation and evaluation, performance appraisal, and the results of the assessment will be announced in a timely manner.

       For the drugs that have not been included in the catalogue management, we should do regular clinical use monitoring and find problems such as abnormal growth in use, no indication, and over-dosage. We must strengthen early warning and find out the cause. Those who have violated the law and regulations must be dealt with seriously.

       The National Health and Health Commission will work with the State Administration of Traditional Chinese Medicine to dynamically adjust the Catalogue.

The first batch of national key monitoring and rational drug list (chemical and biological products)

 
(names not listed in order)

Serial number

Generic name of the drug

1

Ganglioside
 

2

Cerebroside

3

Olaxitan

4

Sodium creatine phosphate

5

Calf serum deproteinization

6

Alprostadil

7

Quke rutin brain protein hydrolysate

8

Compound coenzyme

9

Danshen ligustrazine

10

Invert sugar electrolyte

11

Mouse nerve growth factor

12

Thymopentin

13

Ribonucleic acid II

14

Edaravone

15

Osteopeptide

16

Brain protein hydrolysate

17

Ribonucleic acid

18

Vinpocetine

19

Calf blood deproteinized extract

20

Cinepazide maleate

 

 

Scan the QR code to read on your phone

Contact us

Sales Telephone:0756-7623818

                             0756-7623828

Sales fax:0756-7623805

Complaints Hotline0756-7636858

Mailbox:service@zhtyyy.com

Zhuhai Homologous Pharmaceutical Mobile Website

Copyright © 2019 Zhuhai Tongyuan Pharmaceutical Co., Ltd.  粤ICP备15011330号  Website:300.cn